Keros Therapeutics 

Yahoo Finance • last month

Keros Therapeutics Announces Final Results of Tender Offer

LEXINGTON, Mass., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), today announced the final results of its cash tender offer (the “Tender Offer”) to repurchase up to 10,950,165 shares... Full story

Yahoo Finance • last month

Keros Therapeutics Announces Preliminary Results of Tender Offer

LEXINGTON, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), today announced the preliminary results of its cash tender offer (the “Tender Offer”) to repurchase up to 10,950,165... Full story

Yahoo Finance • 2 months ago

Keros Therapeutics commences tender offer to repurchase up to $194.4 million shares

* Keros Therapeutics (NASDAQ:KROS [https://seekingalpha.com/symbol/KROS]) has commenced a cash tender offer to repurchase up to $194.4 million of common shares, at a purchase price of $17.75 per share. The Company expects to fund the ten... Full story

Yahoo Finance • 2 months ago

Keros Therapeutics To Buyback $181 Mln Of Shares From ADAR1, Pontifax; Plans $194 Mln Tender Offer

(RTTNews) - Keros Therapeutics, Inc. (KROS), a clinical-stage biopharmaceutical company, on Wednesday announced that it has entered into share purchase agreements to buy back all shares held by ADAR1 Capital Management LLC and Pontifax Ven... Full story

Yahoo Finance • 2 months ago

Keros Therapeutics Announces Plan for Return of $375 Million in Excess Capital

Agrees to Repurchase of All Shares Held By ADAR1 Capital Management and Pontifax Venture Capital Plans to Commence Tender Offer to Repurchase up to $194 Million of Additional Shares LEXINGTON, Mass., Oct. 15, 2025 (GLOBE NEWSWIRE) -- K... Full story

Yahoo Finance • 4 months ago

Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences

LEXINGTON, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wi... Full story

Yahoo Finance • 4 months ago

Sector Update: Health Care Stocks Rise Pre-Bell Friday

Health care stocks were rising pre-bell Friday, with The Health Care Select Sector SPDR Fund (XLV) 0 PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 4 months ago

Keros Therapeutics' Duchenne Muscular Dystrophy Treatment Gets FDA's Orphan Drug Designation

(RTTNews) - Keros Therapeutics, Inc. (KROS), a clinical-stage biopharmaceutical company, Wednesday announced that the U.S. Food and Drug Administration granted Orphan Drug designation for KER-065 for the treatment of Duchenne muscular dyst... Full story

Yahoo Finance • 4 months ago

Form 8K Keros Therapeutics Inc For: 20 August

... Full story

Yahoo Finance • 4 months ago

Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy

LEXINGTON, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patie... Full story

Yahoo Finance • 5 months ago

Keros Therapeutics stock price target lowered to $20 at H.C. Wainwright

Investing.com - H.C. Wainwright lowered its price target on Keros Therapeutics (NASDAQ:KROS) to $20.00 from $25.00 on Friday, while maintaining a Buy rating on the stock. According to InvestingPro data, the stock appears undervalued at cur... Full story

Yahoo Finance • 5 months ago

Keros earnings beat by $0.37, revenue topped estimates

Investing.com - Keros (NASDAQ: KROS) reported second quarter EPS of $-0.76, $0.37 better than the analyst estimate of $-1.13. Revenue for the quarter came in at $18.17M versus the consensus estimate of $4.21M. Keros’s stock price closed a... Full story

Yahoo Finance • 5 months ago

Keros to Exclusively Prioritize the Clinical Advancement of KER-065

Company Discontinuing Development of Cibotercept (KER-012) Announces Board and Leadership Changes Designed to Support Streamlined Operational Structure and Strategic Realignment LEXINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Ker... Full story

Yahoo Finance • 5 months ago

Keros Therapeutics Reports Second Quarter 2025 Financial Results

LEXINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wi... Full story

Yahoo Finance • 7 months ago

Keros Announces Return of $375 Million in Excess Capital to Stockholders

LEXINGTON, Mass., June 09, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wi... Full story

Yahoo Finance • 7 months ago

Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference

LEXINGTON, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patie... Full story

Yahoo Finance • 7 months ago

Keros Therapeutics Stops PAH Drug Development, Shrinks Workforce By 45%

Keros Therapeutics Inc (NASDAQ:KROS) released topline data from the TROPOS Phase 2 trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension (PAH) on Wednesday. In December 2024... Full story

Yahoo Finance • 7 months ago

Keros Therapeutics Announces TROPOS Topline Data and Corporate Restructuring

Discontinues Development of Cibotercept in PAH Announces Corporate Restructuring to Align Operations with Ongoing Strategic Priorities LEXINGTON, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”, the “Company”... Full story

Yahoo Finance • 7 months ago

Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Keros’ Director Nominees

Keros Board Best Equipped to Oversee Strategic Review Process and Execute on Ultimate Outcome of that Process ADAR1’s Disruptive and Self-Serving Campaign Stands to Jeopardize the Future Value Maximizing Potential of the Company Keros Ur... Full story

Yahoo Finance • 8 months ago

Keros Reinforces Commitment to Maximizing Stockholder Value

Responds to Recent Public Stockholder Communications Urges Stockholders to Protect Their Investment by Voting “FOR” the Company’s Highly Qualified Director Nominees LEXINGTON, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics,... Full story